Dr Sanjay Chatterjee, MD - Apollo Gleneagles Hospital - Consultant Diabetologist

Dr Sanjay Chatterjee

MD

Apollo Gleneagles Hospital

Consultant Diabetologist

Kolkata, West Bengal | India

Main Specialties: Endocrinology Diabetes & Metabolism

Additional Specialties: Diabetology


Top Author

Dr Sanjay Chatterjee, MD - Apollo Gleneagles Hospital - Consultant Diabetologist

Dr Sanjay Chatterjee

MD

Introduction

Dr. Sanjay Chatterjee was born in Calcutta, India in 1952. He passed MBBS (medical graduation) from Nilratan Sircar Medical College under University of Calcutta in 1977. After completion of Internship and one-year House Physician in Internal Medicine, he passed Diploma in Basic Medical Science from University of Calcutta in 1981. He passed M.D. (Doctor of Medicine), University of Calcutta in 1983. His MD thesis on study of serum lipoprotein profile in patients with coronary heart disease was a pioneering work on lipids. He worked in the Diabetes Clinic of RK Mission Seva Pratishthan hospital, Calcutta for more than five years and did research on diabetes. Subsequently, he completed a one-year certificate program on Diabetes Care from University of Newcastle, Australia. He is at present a Senior Consultant in Nutrition and Diabetes at Apollo Gleneagles Hospital, Kolkata (Calcutta), India since 2003. His areas of interest are Diabetes & Metabolic Syndrome and he has several publications in many international journals in these fields. He is a joint editor of three handbooks on diabetes and is an author and moderator of Diapedia, the internet text-book on diabetes, funded by European Association for Study of Diabetes. Dr. Chatterjee is Reviewer and Editorial Board Member for many international journals. He has been Principal Investigator of several international clinical trials.

Dr. Sanjay Chatterjee is a founder member of Integrated Diabetes & Endocrine Academy or, IDEA – an academic organisation for fostering knowledge in the fields of diabetes and endocrinology. The annual conference of IDEA, called IDEACON, is among the most sought-after conferences in its field in India. IDEACON has furthered the prestige of West Bengal in the fields of diabetes and endocrinology.
In August 2017, Dr. Sanjay Chatterjee has been appointed Sheriff of Calcutta by His Excellency Governor of West Bengal.

Primary Affiliation: Apollo Gleneagles Hospital - Kolkata, West Bengal , India

Specialties:

Additional Specialties:

Research Interests:


View Dr Sanjay Chatterjee’s Resume / CV

Education

Jul 1983
University College of Medicine
M.D.

Experience

Jun 2017
DEVOTE Trial (Inj. Degludeg)
Principal Investigator
CVOT of Inj. Degludeg
Jun 2017
DEVOTE Trial (Inj. Degludeg)
Principal Investigator
CVOT of Inj. Degludeg
Jun 2017
DEVOTE Trial (Inj. Degludeg)
Principal Investigator
CVOT of Inj. Degludeg

Publications

18Publications

624Reads

28Profile Views

6PubMed Central Citations

Management of Asymptomatic Hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement

Diabetes Met Synd Clin Res Rev. 2020; 1

Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

The definition and management of asymtomatic hyperuricemia has been area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymtomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country.

View Article
January 2020
3 Reads

Effects on Metabolic Parameters of Addition of SGLT‐2 Inhibitors on Patients with Type2 Diabetes Inadequately Controlled with DPP‐IV Inhibitors and Metformin

Diabetes Obes Int J 2019, 4(2): 000201

Diabetes and Obesity International Journal

AbstractBackground: Practice guidelines are open regarding choice of therapy after metformin. The second line agent’s insulin(INS), sulphonylureas (SU) and thiazolidinediones (TZD) may cause either hypoglycaemia or weight gain. Dipeptidylpeptidase‐IV (DPP-4) inhibitors are unlikely to produce that. Sodium‐glucose transporter‐2 (SGLT -2) inhibitors arenewer agents with the advantage of weight loss. Indian data regarding combination therapy with Metformin withDPP-4inhibitors plus SGLT-2 inhibitors arescanty; hence this study is relevant .Moreover the number of patients studied,duration of study, study variables and effects of three SGLT-2inhibitors were analyzed separately.Objectives: To study the glycaemic and other metabolic parameters after treatment with SGLT‐2 inhibitors-canagliflozinor, dapagliflozin, or, empagliflozin in type 2 Diabetes (T2DM) patient inadequately controlled (HbA1c >7.5%) with DPP-4inhibitors plus metformin.Methodology: Data of 101 T2DM patients inadequately controlled (HbA1c> 7.5%) with DPP-4 inhibitors plus metforminwho were prescribed canagliflozin 100 mg or, dapagliflozin 5 or 10 mg, or empagliflozin 10 mg or 25 mg once daily withmean follow‐up duration of 23 weeks were analyzed. Subjects receiving INS, SU and TZD were excluded from analysis.Changes in weight, blood pressure, glycaemia, lipids, renal and hepatic parameters were studied. Subgroup analyses weredone to see effects of three SGLT‐2 inhibitors.Results: Results showed that addition of SGLT-2 inhibitors produced favourable effects on all metabolic parametersstudied.Conclusion: Our study shows that addition of SGLT2 inhibitors on existing therapy with DPP-4 inhibitors and metforminproduces favourable effects on metabolic parameters with the advantage of weight loss and without producing majorhypoglycaemic events.Keywords: SGLT-2 inhibitors; DPP-4 inhibitors; Metformin; T2D

View Article
May 2019
407 Reads

1. Observational Study of Saroglitazar on Metabolic Parameters in Indian Patients with Diabetic Dyslipidaemia – A Fifty Eight Weeks of Clinical Experience

. Diabetes Obes Int J. 2018, May 3(3): 000181

Diabetes and Obesity International Journal ISSN: 2574-7770

Background: Earlier we had reported results of our study of treatment with Saroglitazar, in a dose of 4 mg daily, for 14 weeks in 34 patients with diabetic dyslipidemia., and showed significant improvement in both glycemic and lipid parameters. We conducted this 58 weeks follow-up study in 158 patients to determine whether the improvement in glycemic and lipid parameters persisted in long-term follow-up and whether long-term therapy had any effect on the blood pressure, weight, renal and liver functions. Methods: We have studied follow-up data of 158 patients collected from the authors’ clinic databases and analyzed the effect of saroglitazar on metabolic parameters. Data of patients having both baseline and follow-up data were included in the analysis. The mean duration of follow-up was 58 weeks. Saroglitazar was prescribed at a dose of 4 mg daily, in accordance with approved indication and prescribing information, to patients of T2DM and having hypertriglyceridemia (serum TG level ≥150 mg/dl). Patients received treatment as per routine standard of care without any experimentation on any patient. The patients’ physical parameters (weight, blood pressure etc.), serum lipid profile and glycemic parameters (fasting plasma glucose, post-meal plasma glucose,HbA1C) were determined at baseline and at last follow-up visit. Results: After a mean study duration period of 58 weeks of 158 patients with diabetic dyslipidemia, there was significant reduction in triglycerides from 319.88 ± 178.75 mg/dl (mean ± SD) to 174.03 ± 113.62 mg/dl (reduction of 145.84 ± 186.59 mg/dl; p<0.001). Glycosylated hemoglobin (HbA1c) was reduced from 7.91 ± 1.53% (mean ± SD) to7.25 ± 1.38% (reduction of 0.65 ± 1.37%; p<0.001). Other lipid and glycemic parameters such as total cholesterol, low-density lipoprotein, non-high-density lipoprotein, triglyceride/HDLc ratio, fasting and postprandial plasma glucose were also significantly reduced. There were no major adverse events observed or, reported during the entire study period. Conclusion: Our long-term follow-up study showed that dual PPAR α+γ agonist, saroglitazar, could be an effective and safe therapeutic option in adult patients with diabetic dyslipidemia with a persistent and significant improvement in glycemic and lipid parameters and may confer an additional beneficial effect on blood pressure and liver function as well.

View Article
May 2018
78 Reads

Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome

Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address al

World Journal of Diabetes

Cardiovascular death is the leading cause of mortality for patients with type 2 diabetes mellitus. The etiology of cardiovascular disease in diabetes may be divided into hyperglycemia per se and factors operating through components of metabolic syndrome (MetS). Hyperglycemia causes direct injury to vascular endothelium and possibly on cardiac myocytes. MetS is a cluster of risk factors like obesity, hyperglycemia, hypertension and dyslipidemia. The incidence of this syndrome is rising globally. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a group of drugs, which address all components of this syndrome favorably. Experimental evidence suggests that they have favorable actions on myocardium as well. Several compounds belonging to GLP-1RA class are in market now and a large number awaiting their entry. Although, originally this class of drugs emerged as a treatment for type 2 diabetes mellitus, more recent data generated revealed beneficial effects on multiple metabolic parameters. We have studied literature published between 2000 and 2016 to look into effects of GLP-1RA on components of MetS. Results from recently concluded clinical trials suggest that some of the molecules in this class may have favorable effects on cardiovascular outcome.

View Article
August 2016
62 Reads

Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.

Am J Ther 2015 May-Jun;22(3):195-8

1Consultant Physician, Diabetes Clinical Nutrition, Apollo Gleneagles Hospital, Kolkata, India; and 2Fellow, Preventive Cardiology, Brown University & VA Medical Center, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e3182811a8bDOI Listing
February 2016
120 Reads
1.130 Impact Factor

Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.

Sci Rep 2015 Jan 9;5:7706. Epub 2015 Jan 9.

Consultant Endocrinologist, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata 700054, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep07706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287720PMC
January 2015
76 Reads
3 Citations
5.080 Impact Factor

Stratgies to Increase HDL-cholesterol

Chatterjee S, Ghosal S. Strategies to Increase HDL-cholesterol. J Clin Diabetes Metab. (2014). Nov.

Journal of Clinical Diabetes & Metabolism

Coronary heart disease (CHD) is a major cause of morbidity and mortality all over the world. Abnormalities of serum lipids were implicated as an important cause of CHD for a long time.

View Article
November 2014
59 Reads

Diabetic Dyslipidemia - Role of Saroglitazar

Majumder A, Chatterjee S (2014) Diabetic Dyslipidemia - Role of

Medicinal Chemistry

‘Diabetic dyslipidemia’ (combination of raised triglyceride levels, raised small-dense Low-density lipoprotein particles and low high-density lipoprotein cholesterol levels) is the most prominent risk factor of atherosclerosis and cardiovascular disease. Despite statin therapy and LDL-lowering, a high residual risk of cardiovascular events persists. High triglyceride levels and low high-density lipoprotein cholesterol levels singly and collectively increase the risk of cardiovascular events in type 2 diabetes mellitus and guidelines recommend modifying these secondary therapeutic targets to provide additional vascular protection.Addition of a fibrate or niacinareoptions for combination with a statin to reduce atherogenic dyslipidemia and are clearly effective at raising high-density lipoprotein cholesterol levels and lowering triglycerides.Addition of high dose omega-3 fatty acids (2-3 gm/day) with a statin are also effective in lowering triglyceride, but their effects on cardiovascular events remain uncertain and are complicated with safety issues. Saroglitazar is a novel dual Peroxisome Proliferator-Activated Receptors-α/γ agonist and the first glitazar approved in the world for the treatment of diabetic dyslipidemia by Drug Controller General of India in June 2013. Saroglitazar (2 mg and 4 mg) therapy has shown significant (45%) reduction in triglycerides, significant reduction of other atherogenic lipids (Low-density lipoprotein, very-low density lipoprotein, total cholesterol and apolipoprotein-B) and significant improvement of glycemic status, with relatively free from side effects. It has emerged with a hope to further reduce the incidence of cardiovascular disease among statin treated diabetic subjects. However, the trial populations were small and toxicity data may emerge with increasing use of this drug. Moreover, in absence of outcome studies and large multi-center longitudinal follow up data, the clinical cardiovascular efficacy is uncertain till date

View Article
September 2014
74 Reads

Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.

J Diabetes 2014 May 27;6(3):237-42. Epub 2013 Aug 27.

Apollo Gleneagles Hospital, Kolkata, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-0407.12078DOI Listing
May 2014
112 Reads
3 Citations

Discovery of insulin--from isletin to degludec and beyond.

J Indian Med Assoc 2013 Nov;111(11):729-32, 734

View Article

Download full-text PDF

Source
November 2013
108 Reads

Glycosylated Hemoglobin - Its Use in the Diagnosis and Management of Diabetes Mellitus

Indian Medical Journal. 1984 April; 78(4):53 - 55.

Indian Medical Journal

View Article
April 1984
67 Reads

Kartagener's syndrome with situs inversus totalis, agenesis of frontal sinuses and bilateral cervical rib

J Indian Med Assoc. 1980 May 16;74(10):192-4. PubMed PMID: 6969764.

J Indian Med Assoc

Not Available

View Article
May 1980
62 Reads

Top co-authors

Partha Sardar
Partha Sardar

University of Utah

2
Anirban Majumder
Anirban Majumder

KPC Medical College, Kolkata, India

2
Anasua Chakraborty
Anasua Chakraborty

Thomas Jefferson University Hospital

2
Ghanshyam Goyal
Ghanshyam Goyal

Department of Minimal Access & Bariatric Surgery ILS Hospitals

1
Subir Ray
Subir Ray

University of Massachusetts Medical School

1